Conversations about health AI over the past few years have often centered on a familiar question: Is the model smart enough, is the algorithm advanced enough, and is the accuracy high enough? Today, that conversation is shifting. What increasingly determines whether a health AI product can earn long-term trust and enter more serious clinical and commercial environments is not how intelligent it appears, but whether it is grounded in real-world evidence.

Health AI has never been a purely technical issue. It ultimately faces patients, clinicians, healthcare institutions, regulators, and payment systems. Once an AI system enters real care settings, it must answer harder questions than model performance alone: Does it remain stable across institutions, populations, and data structures? Does it improve outcomes in practice, or does it create new forms of bias? Can it be continuously monitored, validated, and refined? These questions cannot be answered only by training-set performance or a limited number of published studies. They require real-world data and real-world evidence.

In other words, competition in health AI is shifting from “who has AI” to “who has evidence.” This is not simply a regulatory tightening. It reflects a maturing market. Once health AI enters real clinical environments, errors do not occur evenly. They often concentrate in the most complex, fragile, and underserved patient populations. That is why one of the next defining advantages in health AI will be whether a company can build outcome-grounded evidence.

This is especially important for Chinese health AI companies, device developers, and digital health teams. Many of them already have early validation, engineering capability, and algorithm strength in their home market. But once they consider the U.S. market, the questions change. The market does not only ask whether the product works. It asks whether the product can be trusted over time. And sustained trust is not built on a one-time premarket story. It is built on an evidence structure that is much closer to a total product lifecycle approach.

That is why we increasingly believe that real-world evidence will not remain a “nice-to-have” supplement. It is becoming a new gatekeeper for health AI. It affects regulatory acceptability, commercial credibility, and product iteration quality. For companies that want to build for the long term, real-world evidence is not only an external proof point. It is also an internal optimization tool. Without real-world feedback and outcomes support, AI systems struggle to improve in a meaningful way and to understand their own limits across settings and populations.

This is also why BioLife no longer views health AI simply as a matter of exporting algorithms or selling software. We are increasingly focused on a deeper set of questions: Does the system have a clear use case? Can it find the right research-first entry or market entry path? Can it build real-world evidence support? Can it strengthen its U.S. foundation through clinical data collaboration, research validation, and evidence generation?

For Chinese health AI companies seeking to enter the U.S. market today, the key is not to sound more advanced than others. It is to develop a more mature judgment early: the next stage of competition will not be won by who talks best about AI, but by who understands evidence first. In that sense, real-world evidence is no longer just an advantage for health AI. It is becoming a new gatekeeper.

This article reflects BioLife’s perspective on the topic.